Morten Nielsen

7PUBLICATIONS
26CO-AUTHORS
Molecular targetsTumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Dec 21, 2023
LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma.

Morten Nielsen, Tine Monberg, Vibeke Sundvold

|Aug 15, 2022
Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post-PD-1 Immunotherapy.

Morten Nielsen, Mario Presti, Zsofia Sztupinszki

|Oct 05, 2021
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.

Anders Handrup Kverneland, Christopher Aled Chamberlain, Troels Holz Borch

|Jul 02, 2021
Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma.

Troels Holz Borch, Katja Harbst, Aynal Haque Rana

|Nov 17, 2020
Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8+ T Cells in Non-Melanoma Cancers Compared to Melanoma.

Aishwarya Gokuldass, Arianna Draghi, Krisztian Papp

|May 31, 2020
In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes.

Morten Nielsen, Anders Krarup-Hansen, Dorrit Hovgaard

Pageof 2

Frequent Collaborators

4 joint publications

Troels Holz Borch

3 joint publications

Özcan Met

3 joint publications

Christopher Aled Chamberlain

3 joint publications

Marco Donia